Elevate Decisive Coronary Care with CCTA + Heartflow
CCTA + Heartflow enables you to assess blood flow throughout the entire coronary tree, determining the need for revascularization. Then go further for your patients by quantifying and characterizing plaque to reveal hidden risk, personalize care, and manage CAD.
Guideline-Backed Diagnostic Power
Coronary CTA is a Class 1A AHA/ACC guideline-recommended test for assessment of intermediate-high risk stable chest pain. Heartflow FFRCT adds the physiology you need, without extra radiation or additional testing.
Anatomy Alone Is Not Enough.
Adding Heartflow FFRCT to a Coronary CTA enables understanding of coronary physiology before going to the cath lab. Not all stenoses cause functionally significant CAD. Traditional stress testing leaves plaque burden and composition unmeasured and unaddressed, potentially increasing patient risk.
1 in 3
lesions with a
30-50% stenosis
are functionally
significant1
1 in 2
lesions with a
50-70% stenosis
are functionally
significant1
1 in 4
lesions with a
70-90% stenosis
are NOT functionally
significant1
Up to 50%
false-positive rate
associated with traditional stress testing in suspected CAD patients2-5
Up to 35%
false-negative rate
associated with traditional stress testing in suspected CAD patients2-5
One Scan. Complete Confidence.
Assess anatomy, physiology, and plaque composition in a single pathway—streamlining your consult, cath lab referrals, and patient management. A CAD diagnostic pathway that begins with CCTA compared to traditional testing reduces longterm cardiac event rates by up to 41%.6
Heartflow FFRCT achieves an AUC of 0.94 outperforming CCTA alone (0.83), SPECT (0.70), and PET (0.87)7, 8
78%
more likely to identify patients in need of revascularization.9
69%
decrease in unnecessary invasive coronary angiographies (ICAs).9
Nearly
50%
of patients with a Calcium Score of 0 were reclassified to a more appropriate approach with Plaque Analysis10